Related Experiment Video

Updated: May 14, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancer

Tsukasa Seya1, Masahiro Azuma, Misako Matsumoto

  • 1Hokkaido University, Graduate School of Medicine, Department of Microbiology and Immunology, Sapporo, 060-8638 , Japan. seya-tu@pop.med.hokudai.ac.jp

Expert Opinion on Therapeutic Targets
|February 19, 2013
PubMed
Abstract

Insights

RNA adjuvants activate distinct immune pathways for cancer immunotherapy. MAVS activation drives cytokine production, while TICAM-1 in dendritic cells promotes anti-tumor immunity, offering a promising therapeutic strategy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • RNA duplexes act as agonists for pattern-recognition receptors, showing potential as cancer immunotherapy adjuvants.
  • These RNA duplexes stimulate cytokines, interferons (IFNs), and cellular effectors through Toll-like receptor 3/Toll-interleukin-1 receptor domain-containing adapter inducing interferon-beta (TLR3/TICAM-1) and melanoma differentiation-associated gene 5/mitochondrial antiviral signaling protein (MDA5/MAVS) pathways.

Purpose of the Study:

  • To elucidate the predominant innate immune pathway responsible for tumor immunity induction by RNA adjuvants.

Main Methods:

  • Utilized knockout (KO) mouse models to investigate the roles of MAVS and TICAM-1 pathways in response to RNA adjuvants.
  • Assessed cytokine and IFN production, dendritic cell maturation, and anti-tumor cellular effector generation (NK and CTL).

Main Results:

  • Systemic MAVS pathway activation is crucial for robust cytokine and IFN production.
  • TICAM-1 pathway activation within dendritic cells is essential for driving NK and CTL effector functions.
  • MAVS activation can lead to endotoxin-like cytokinemia, whereas TICAM-1 activation does not.
  • The TICAM-1 pathway shows minimal acceleration of tumor progression compared to TLR/MyD88.

Conclusions:

  • Distinct pathways mediate different aspects of anti-tumor immunity: MAVS for systemic cytokine response and TICAM-1 for dendritic cell-mediated cellular immunity.
  • While therapeutic efficacy in humans is yet to be determined, optimizing TLR3 agonists for reduced toxicity and appropriate dosing is a key goal for cancer immunotherapy.
  • Further research into RNA duplex formulations is necessary for developing promising candidates for clinical application.

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods09:23

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...